Sentinel Oncology today announces a further round of funding to progress its novel chemical technologies for developing new anticancer agents.
Sentinel set to progress novel anti-cancer technology with new investment
Sentinel has made significant progress in validating their targeted small molecule approach for cancer treatment. They have a strong pipeline with a lead molecule that will shortly enter in-vivo studies, and is expected to be their first candidate to partner with a pharmaceutical major.
Sentinel has also established proprietary technology for removing unwanted side effects in lead molecules from which the company anticipates generating early revenue streams.
To finance the next phase of growth the company has raised further funding of 450,000 from:
Medeor was founded by Professor David Tapolczay and is a consortium of pharmaceutical industry experts who are investing their own funds through the company. Their extensive pharmaceutical experience brings significant added value to the company. Professor David Tapolczay who has over 20 years experience of Pharmaceutical and Agrochemical R&D management will join the Sentinel board of directors.
Bob Boyle, Co-Founder of Sentinel Oncology said 'I am delighted with the investment, the experience each group brings and to welcome Professor Tapolczay to the board of directors. The support will enable us to evolve and strengthen our pipeline in the coming year and help us build strong relationships with our future pharmaceutical partners. '
Geraldine Rodgers, Cambridge Enterprise Seed Funds, said 'I'm delighted to have such experienced investors alongside who bring solid experience to help translate the exciting Sentinel technology into real products.'
The company was founded at the beginning of 2005 by Bob Boyle, Stuart Travers and Gavin Simpson. Following receipt of a grant for Research and Development from the East of England Development Agency, Cambridge University Cancer Biology specialist Professor Ashok Venkitaraman joined the board and the Cambridge Enterprise Seed Funds made its first investment of 100,000 into the company.
Sentinel has built a pipeline of small molecules designed to target hallmarks of solid tumours. In particular Sentinel is developing small molecule inhibitors that are activated selectively under tumour Hypoxia (the low oxygen environment found in all solid tumours). Our vision is to develop drugs in oncology that are void of the systemic toxicities often associated with chemotherapeutics.
Further information on Sentinel Oncology can be found at: www.sentineloncology.com
The University Challenge Fund is part of Cambridge Enterprise Seed Funds. Cambridge Enterprise facilitates the commercial development of intellectual property (IP) developed at the University of Cambridge and the provision of consultancy services by academics.
Cambridge Enterprise is one of the United Kingdom's leading knowledge transfer offices providing consultancy and licensing patents and other IP to existing companies, both large and small as well as to spinouts formed to exploit University technology. For the academic year ending 2006, 61 licences were entered into and income from licensing exceeded 3.3 million. Additionally consultancy agreements generated 2.9 million.
Working together with angels, venture capital funds, University staff and students, Cambridge Enterprise facilitates the formation of around thirty new companies each year (about five of which are based on University-owned intellectual property).
Further information on Cambridge Enterprise can be found at www.enterprise.cam.ac.uk
For further information please contact: Shirley Jamieson, Head of Marketing, Cambridge Enterprise Limited Tel: 01223 760 339 email: firstname.lastname@example.org
Cambridge Enterprise exists to help University of Cambridge inventors, innovators and entrepreneurs make their ideas and concepts more commercially successful for the benefit of society, the UK economy, the inventors and the University.